Bedrijfsberichten · 5-11-20261 min lezen
Anaheim Bio Launches with €40 Million Series A Financing to Advance ANA-1 for Calcium Pyrophosphate Deposition Disease into the Clinic
Lokale automatische vertaling · Oorspronkelijke brontaal
Samenvatting
Anaheim spun out of Alesta Therapeutics prior to its recent acquisition by BioMarin Financing provided by Droia Ventures, Frazier Life Sciences, RTW, Novartis Venture Fund, RV Invest and Thuja Capital Runway into…